-
公开(公告)号：US07977104B2
公开(公告)日：2011-07-12
申请号：US11528883
申请日：2006-09-27
CPC分类号： G01N33/76 , C07K14/59 , C07K16/26 , G01N33/57434 , G01N33/57449 , G01N2333/59 , Y10S435/971 , Y10S436/811 , Y10S436/814 , Y10S436/818
摘要： The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.
-
2.发明授权Methods and reagents for determining the amount of hLHβ core fragment in a sample 失效用于测定样品中hLHbeta核心片段的量的方法和试剂公开(公告)号：US07655410B2
公开(公告)日：2010-02-02
申请号：US10361652
申请日：2003-02-10
CPC分类号： C07K16/36 , G01N33/76 , G01N2333/59 , G01N2800/52
摘要： The present invention provides a method for predicting the likely timing of the onset of menopause for a perimenopausal female subject by determining the amount of hLHβcf in a sample from the subject comprising the steps of: (a) contacting a sample from the subject with an antibody which specifically binds to hLHβcf without substantially cross-reacting with hLH, hLHβ or hLHβcf, under conditions permitting formation of a complex between the antibody and hLHβcf; (b) measuring the amount of complex formed, so as to thereby determine the amount of hLHβcf in the sample; and (c) comprising the amount of hLHβcf in the subject's sample determined in step (b) with either (i) the amount determined for known postmenopausal female subject or (ii) the amount determined for a sample from a known premenopausal female subject, wherein an amount of hLHβcf in the sample similar to the amount of hLHβcf in the known postmenopausal sample indicates temporal proximity to the onset of menopause, and an amount of hLHβcf in the sample similar to the amount of hLHβcf in the known premenopausal sample indicates temporal distance from the onset of menopause for the subject. AS described herein amount is both concentration and pattern of measurement of concentrations in one or more consecutive urine specimens.
摘要翻译： 本发明提供了一种通过确定来自受试者的样品中的hLHbetacf的量来预测围绝经期女性受试者的绝经发作的可能时机的方法，包括以下步骤：（a）使来自受试者的样品与抗体 其特异性结合hLHbetacf而不与hLH，hLHbeta或hLHbetacf基本上交叉反应，在允许形成抗体和hLHbetacf之间的复合物的条件下; （b）测量形成的复合物的量，从而确定样品中hLHetetf的量; （c）包含在步骤（b）中确定的受试者样品中的hLHbetacf的量与（i）已知绝经后女性受试者确定的量或（ii）从已知绝经前女性受试者确定的样品量，其中 与已知绝经后样品中hLHbetacf的量相似的样品中的hLHbetacf的量表明与绝经期的开始的时间接近，并且与已知绝经前样品中hLHbetacf的量相似的hLHbetacf的量表示与 该主题的更年期发病。 如本文所述，量是在一个或多个连续尿标本中浓度和浓度测量的模式。
-
公开(公告)号：US07399636B2
公开(公告)日：2008-07-15
申请号：US10335115
申请日：2002-12-31
CPC分类号： G01N33/76 , C07K14/59 , C07K16/26 , G01N33/57434 , G01N33/57449 , G01N2333/59 , Y10S435/971 , Y10S436/811 , Y10S436/814 , Y10S436/818
摘要： The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG is a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.
摘要翻译： 本发明提供了通过确定样品中hCG的早期妊娠相关分子同种型的量来预测受试者的妊娠结局的方法。 本发明还提供了一种用于确定样品中人绒毛膜促性腺激素（hCG）的早期妊娠相关分子同种型的量的方法。 本发明还提供了用于确定早期妊娠相关hCG是样品的量的诊断试剂盒。 本发明另外提供了与人绒毛膜促性腺激素的早期怀孕相关分子同种型特异性结合的抗体。 最后，本发明提供了检测样品中滋养层细胞或非滋养层恶性肿瘤的方法。
-
4.发明授权Determination of the amount of hLH&bgr; core fragment in a sample from a subject and uses thereof 失效来自受试者的样品中hLHbeta核心片段的量的测定及其用途公开(公告)号：US06521416B1
公开(公告)日：2003-02-18
申请号：US09630273
申请日：2000-08-01
IPC分类号： C12Q158
CPC分类号： C07K16/36 , G01N33/76 , G01N2333/59 , G01N2800/52
摘要： The present invention provides a method for predicting the likely timing of the onset of menopause for a perimenopausal female subject by determining the amount of hLH&bgr;cf in a sample from the subject comprising the steps of: (a) contacting a sample from the subject with an antibody which specifically binds to hLH&bgr;cf without substantially cross-reacting with hLH, hLH&bgr; or hLH&bgr;cf, under conditions permitting formation of a complex between the antibody and hLH&bgr;cf; (b) measuring the amount of complex formed, so as to thereby determine the amount of hLH&bgr;cf in the sample; and (c) comprising the amount of hLH&bgr;cf in the subject's sample determined in step (b) with either (i) the amount determined for known postmenopausal female subject or (ii) the amount determined for a sample from a known premenopausal female subject, wherein an amount of hLH&bgr;cf in the sample similar to the amount of hLH&bgr;cf in the known postmenopausal sample indicates temporal proximity to the onset of menopause, and an amount of hLH&bgr;cf in the sample similar to the amount of hLH&bgr;cf in the known premenopausal sample indicates temporal distance from the onset of menopause for the subject. AS described herein amount is both concentration and pattern of measurement of concentrations in one or more consecutive urine specimens.
摘要翻译： 本发明提供了一种通过确定来自受试者的样品中的hLHbetacf的量来预测围绝经期女性受试者的绝经发作的可能时机的方法，包括以下步骤：（a）使来自受试者的样品与抗体 其特异性结合hLHbetacf而不与hLH，hLHbeta或hLHbetacf基本上交叉反应，在允许形成抗体和hLHbetacf之间的复合物的条件下; （b）测量形成的复合物的量，从而确定样品中hLHetetf的量; （c）包含在步骤（b）中确定的受试者样品中的hLHbetacf的量与（i）已知绝经后女性受试者确定的量或（ii）从已知绝经前女性受试者确定的样品量，其中 与已知绝经后样品中hLHbetacf的量相似的样品中的hLHbetacf的量表明与绝经期的开始的时间接近，并且与已知绝经前样品中hLHbetacf的量相似的hLHbetacf的量表示与 该主题的更年期发病。 如本文所述，量是在一个或多个连续尿标本中浓度和浓度测量的模式。
-
5.发明申请Determination of the amount of hLHB core fragment in a sample from a subject and uses thereof 审中-公开来自受试者的样品中hLHB核心片段的量的测定及其用途公开(公告)号：US20110262938A1
公开(公告)日：2011-10-27
申请号：US12658098
申请日：2010-02-01
IPC分类号： G01N33/74
CPC分类号： C07K16/36 , G01N33/76 , G01N2333/59 , G01N2800/52
摘要： The present invention provides a method for predicting the likely timing of the onset of menopause for a perimenopausal female subject by determining the amount of hLHβcf in a sample from the subject comprising the steps of: (a) contacting a sample from the subject with an antibody which specifically binds to hLHβcf without substantially cross-reacting with hLH, hLHβ or hLHβcf, under conditions permitting formation of a complex between the antibody and hLHβcf; (b) measuring the amount of complex formed, so as to thereby determine the amount of hLHβcf in the sample; and (c) comprising the amount of hLHβcf in the subject's sample determined in step (b) with either (i) the amount determined for known postmenopausal female subject or (ii) the amount determined for a sample from a known premenopausal female subject, wherein an amount of hLHβcf in the sample similar to the amount of hLHβcf in the known postmenopausal sample indicates temporal proximity to the onset of menopause, and an amount of hLHβcf in the sample similar to the amount of hLHβcf in the known premenopausal sample indicates temporal distance from the onset of menopause for the subject. AS described herein amount is both concentration and pattern of measurement of concentrations in one or more consecutive urine specimens.
摘要翻译： 本发明提供了一种通过确定受试者的样品中hLH和bgr的量来预测围绝经期女性受试者的绝经发作的可能时机的方法，包括以下步骤：（a）将来自受试者的样品与 特异性结合hLH和bgr的抗体，其与hLH，hLH和bgr基本上不具有交叉反应; 或hLH＆bgr; cf，在允许形成抗体与hLH和bgr之间的复合物的条件下; （b）测量形成的复合物的量，从而确定样品中的hLH＆bgr; cf的量; （c）包括在步骤（b）中确定的受试者样品中的hLH和bgr的量，其中（i）已知绝经后女性受试者确定的量或（ii）来自已知绝经前女性受试者的样品的量 其中与已知绝经后样品中的hLH和bgr的量相似的样品中的hLH和bgr的量表示与绝经发生的时间接近，并且样品中的hLH和bgr的量与hLH和bgr的量相似; 在已知的绝经前样本中，cf表示与受试者的绝经期开始的时间距离。 如本文所述，量是在一个或多个连续尿标本中浓度和浓度测量的模式。
-
公开(公告)号：US20110256554A1
公开(公告)日：2011-10-20
申请号：US13150791
申请日：2011-06-01
CPC分类号： G01N33/76 , C07K14/59 , C07K16/26 , G01N33/57434 , G01N33/57449 , G01N2333/59 , Y10S435/971 , Y10S436/811 , Y10S436/814 , Y10S436/818
摘要： The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.
摘要翻译： 本发明提供了通过确定样品中hCG的早期妊娠相关分子同种型的量来预测受试者的妊娠结局的方法。 本发明还提供了一种用于确定样品中人绒毛膜促性腺激素（hCG）的早期妊娠相关分子同种型的量的方法。 本发明还提供了用于确定样品中早期妊娠相关hCG的量的诊断试剂盒。 本发明另外提供了与人绒毛膜促性腺激素的早期怀孕相关分子同种型特异性结合的抗体。 最后，本发明提供了检测样品中滋养层细胞或非滋养层恶性肿瘤的方法。
-
公开(公告)号：US07198954B1
公开(公告)日：2007-04-03
申请号：US09630215
申请日：2000-08-01
CPC分类号： G01N33/76 , C07K16/26 , G01N2800/368 , Y10S436/811
摘要： The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.
-
公开(公告)号：US06500627B1
公开(公告)日：2002-12-31
申请号：US09017976
申请日：1998-02-03
IPC分类号： G01N33543
CPC分类号： G01N33/76 , C07K14/59 , C07K16/26 , G01N33/57434 , G01N33/57449 , G01N2333/59 , Y10S435/971 , Y10S436/811 , Y10S436/814 , Y10S436/818
摘要： The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG is a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.
摘要翻译： 本发明提供了通过确定样品中hCG的早期妊娠相关分子同种型的量来预测受试者的妊娠结局的方法。 本发明还提供了一种用于确定样品中人绒毛膜促性腺激素（hCG）的早期妊娠相关分子同种型的量的方法。 本发明还提供了用于确定早期妊娠相关hCG是样品的量的诊断试剂盒。 本发明另外提供了与人绒毛膜促性腺激素的早期怀孕相关分子同种型特异性结合的抗体。 最后，本发明提供了检测样品中滋养层细胞或非滋养层恶性肿瘤的方法。
-
公开(公告)号：US20140212897A1
公开(公告)日：2014-07-31
申请号：US14228720
申请日：2014-03-28
IPC分类号： G01N33/76 , C07K14/59 , G01N33/574 , C07K16/26
CPC分类号： G01N33/76 , C07K14/59 , C07K16/26 , G01N33/57434 , G01N33/57449 , G01N2333/59 , Y10S435/971 , Y10S436/811 , Y10S436/814 , Y10S436/818
摘要： The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.
-
公开(公告)号：US08691585B2
公开(公告)日：2014-04-08
申请号：US13150791
申请日：2011-06-01
CPC分类号： G01N33/76 , C07K14/59 , C07K16/26 , G01N33/57434 , G01N33/57449 , G01N2333/59 , Y10S435/971 , Y10S436/811 , Y10S436/814 , Y10S436/818
摘要： The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.
摘要翻译： 本发明提供了通过确定样品中hCG的早期妊娠相关分子同种型的量来预测受试者的妊娠结局的方法。 本发明还提供了一种用于确定样品中人绒毛膜促性腺激素（hCG）的早期妊娠相关分子同种型的量的方法。 本发明还提供了用于确定样品中早期妊娠相关hCG的量的诊断试剂盒。 本发明另外提供了与人绒毛膜促性腺激素的早期怀孕相关分子同种型特异性结合的抗体。 最后，本发明提供了检测样品中滋养层细胞或非滋养层恶性肿瘤的方法。
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.017 秒)
